Know Cancer

or
forgot password

Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer


Phase 2
18 Years
N/A
Not Enrolling
Both
Colorectal Cancer

Thank you

Trial Information

Phase II Trial of RAD001 in Patients With Refractory Colorectal Cancer


Study is completed and closed.


Inclusion Criteria:



- Metastatic colorectal cancer refractory to at least 2 chemo/biologic regimens

- Measurable disease

- ECOG 0-2

Exclusion Criteria:

- CNS disease

- Chemotherapy or radiotherapy < 4 weeks prior

- Active bleeding diathesis

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Philip Gold, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Swedish Cancer Institute

Authority:

United States: Food and Drug Administration

Study ID:

CRAD0012467

NCT ID:

NCT00337545

Start Date:

May 2006

Completion Date:

April 2007

Related Keywords:

  • Colorectal Cancer
  • Metastatic
  • Refractory
  • Colorectal Neoplasms

Name

Location
Swedish Cancer Institute Seattle, Washington  98104